New therapeutic targets in the management of urothelial carcinoma of the bladder
Sverrisson EF +2 more
openalex +1 more source
Benign Tumor Mimicking Invasive Urothelial Carcinoma: Inverted Urothelial Papilloma of the Bladder [PDF]
Imane OUJGUENNA
openalex +1 more source
RNA Modifications: Current Understandings and Future Perspectives
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao +7 more
wiley +1 more source
Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway [PDF]
Gangjun Yuan +11 more
openalex +1 more source
Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies
Tumors are no longer viewed as sterile but dynamic ecosystems harboring low‐biomass intratumoral microbiota. These microbes, derived from gut, oral cavity, or circulation, shape tumorigenesis and therapy response via core mechanisms: immunomodulation (regulating T cells, macrophages), metabolic reprogramming (SCFAs, indoles, bile acids), chronic ...
Haoling Zhang +8 more
wiley +1 more source
Exploring the toxicological impact of N-nitrosodimethylamine (NDMA) exposure on bladder urothelial carcinoma (BLCA) through network toxicology, machine learning, and multi-dimensional bioinformatics analysis. [PDF]
Shi Z +6 more
europepmc +1 more source
Primary plasmacytoid urothelial carcinoma of the urinary bladder
Aiko NATSUME +6 more
openalex +1 more source
Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Jiajin Wu +4 more
wiley +1 more source
Targeting Tumor Stroma: Current Challenges and Future Directions
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang +7 more
wiley +1 more source
Intra-individual Comparative Study of Dynamic and Pharmacocavernography [PDF]
Sommerkamp, H. +2 more
core +1 more source

